PATENT CLAIM ANALYSIS

Application Number: 16127542
Application Type: Utility
Filing Date: 2018-09
Publication Date: 2019-01
Patent Classification: ["514", "555000"]

Abstract:
Methods of treating renal cancer, including renal cell carcinoma, using bezafibrate are disclosed herein. Bezafibrate can be administered as a monotherapy or as part of a comprehensive treatment program, which can also include administration with other anti-cancer drugs, surgical treatments or exposure to ionizing radiation.

Claim (Index 24):
The composition according to  claim 21 , wherein the at least one additional therapeutic agent comprises sunitinib.

Metadata:
- Claim Count in Document: 26.0
- Percentile: 97.0
- Lexical Diversity: 1.2439
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15653814', '15645544', '15833430', '15637007', '15524844']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7957879741576459
- 35 USC 102 Novelty (BERT): 0.5450966872131118
- Combined Prediction Score: 0.7707188454631925
- Mean Citation Score: 310.05103
- Max Citation Score: 414.8433
- Similarity Product: 251.61172145812512

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test